PIERIS PHARMACEUTICALS INC. news, videos and press releases - Page 3
For more news please use our advanced search feature.
PIERIS PHARMACEUTICALS INC. - More news...
PIERIS PHARMACEUTICALS INC. - More news...
- Pieris Pharmaceuticals to Host First Quarter 2021 Investor Call and Provide Corporate Update on May 17, 2021
- Pieris Pharmaceuticals and Boston Pharmaceuticals Enter into an Exclusive Worldwide Product License for PRS-342, a 4-1BB/GPC3 Immuno-Oncology Bispecific
- Pieris Pharmaceuticals Presents Updated Phase 1 Monotherapy Data for 4-1BB/HER2 Bispecific Cinrebafusp Alfa and Preclinical Data for 4-1BB/PD-L1 Bispecific PRS-344/S095012 at 2021 AACR Annual Meeting
- Pieris Pharmaceuticals Reports Full-Year 2020 Financial Results and Provides Corporate Update
- Pieris Announces Amendment of Existing Immuno-oncology Multi-target Collaboration with Seagen, a Clinical Trial and Supply Agreement to Evaluate Cinrebafusp Alfa (PRS-343) in Combination with TUKYSA(R) (tucatinib) in Gastric Cancer, and Strategic Equity Investment by Seagen
- Pieris Pharmaceuticals to Host Full-Year 2020 Investor Call and Provide Corporate Update on March 30, 2021
- Pieris Pharmaceuticals to Participate in the Cowen 41st Annual Health Care Conference
- FDA Lifts Partial Clinical Hold on PRS-343 Phase 1 Studies
- Pieris Pharmaceuticals to Participate in Upcoming Investor Conferences
- Pieris Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Corporate Update
- Pieris Pharmaceuticals to Host Third Quarter 2020 Investor Call and Corporate Update on November 4, 2020
- Pieris Pharmaceuticals Presents Updated Data from Phase 1 Monotherapy and Atezolizumab Combination Studies of 4-1BB/HER2 Bispecific PRS-343 at the European Society for Medical Oncology (ESMO) Virtual Congress 2020
- Pieris Pharmaceuticals to Participate in Upcoming Investor Conferences
- Pieris Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Corporate Update
- Pieris and Lilly Enter Into a Clinical Trial Collaboration to Evaluate Combination of PRS-343 With Ramucirumab and Paclitaxel in Gastric Cancer
- Pieris Pharmaceuticals to Host Second Quarter 2020 Investor Call and Corporate Update on August 10, 2020
- Pieris Pharmaceuticals Announces Oral Presentation of Phase 1 Data for 4-1BB/HER2 Bispecific PRS-343 at European Society for Medical Oncology (ESMO) Virtual Congress 2020
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pieris Pharmaceuticals, Inc. - PIRS
- Pieris Pharmaceuticals Announces Partial Clinical Hold On PRS-343
- Pieris Pharmaceuticals Announces Virtual 2020 Annual Meeting of Stockholders
- Pieris Pharmaceuticals to Present at the Jefferies 2020 Virtual Healthcare Conference
- Pieris Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Corporate Update
- Pieris Pharmaceuticals to Host First Quarter 2020 Investor Call and Corporate Update on May 11, 2020
- Pieris Pharmaceuticals Reports Full-Year 2019 Financial Results And Provides Corporate Update
- Pieris Pharmaceuticals to Host Full-Year 2019 Investor Call and Corporate Update on March 12, 2020
- Pieris Pharmaceuticals to Participate in Upcoming Scientific and Investor Conferences
-
Pieris Pharmaceuticals, Inc. - PIRS Stock Chart Technical Analysis for 02-03-2020
-
Pieris Pharmaceuticals, Inc. - PIRS Stock Chart Technical Analysis for 01-28-2020
- Pieris Pharmaceuticals Announces Asthma-focused Translational Research Collaboration with the University of Pittsburgh
- Pieris Pharmaceuticals to Participate in Upcoming Investor Conferences
